Baudax Bio files for bankruptcy a year after halting sales of its pain medicine Anjeso

In December, Baudax Bio filed a notice with the SEC stating that its financial struggles “raise substantial doubt about [the company’s] ability to continue as a going concern.”
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks